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Background: Most studies of outcomes after myocardial infarction (MI) focus on the acute phase after the index
event. We assessed mortality and morbidity trends after the first year in survivors of acute MI, by conducting a
systematic literature review.
Methods: Literature searches were conducted in Embase, MEDLINE, and the Cochrane Database of Systematic
Reviews to identify epidemiological studies of long-term (>10 years) mortality and morbidity trends in individuals
who had experienced an acute MI more than 1 year previously.
Results: Thirteen articles met the inclusion criteria. Secular trends showed a consistent decrease in mortality and
morbidity after acute MI from early to more recent study periods. The relative risk for all-cause death and
cardiovascular outcomes (recurrent MI, cardiovascular death) was at least 30% higher than that in a general
reference population at both 1–3 years and 3–5 years after MI. Risk factors leading to worse outcomes after MI
included comorbid diabetes, hypertension and peripheral artery disease, older age, reduced renal function, and
history of stroke.
Conclusions: There have been consistent improvements in secular trends for long-term survival and cardiovascular
outcomes after MI. However, MI survivors remain at higher risk than the general population, particularly when
additional risk factors such as diabetes, hypertension, or older age are present.
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The incidence of acute myocardial infarction (AMI) and
case-fatality rates after AMI are declining in most coun-
tries, especially in those with high per capita incomes
[1–3]. However, the aging world population, population
growth, and the rising prevalence of long-term survivors
of AMI mean that the burden of disease is generally in-
creasing [1]. Secular trends in reduced morbidity and
mortality in individuals with acute coronary syndromes,
including AMI, are underpinned by advances in treat-
ment and by the implementation of processes of care,
such as networks for the treatment of ST-elevation MI
(STEMI) [4, 5].* Correspondence: Saga.Johansson@astrazeneca.com
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(http://creativecommons.org/publicdomain/zeSurvivors of AMI are at high risk of a recurrent myo-
cardial infarction (MI), as well as other manifestations of
cardiovascular (CV) disease such as stroke [6–8]. Most
studies of post-MI outcomes focus on the acute phase
after the index event, with few data available for follow-
up beyond the first year. However, although the risk of
CV events is highest in the first year post-index MI, it
remains elevated in subsequent years [9, 10].
The objective of this systematic literature review was
to assess whether morbidity and mortality in survivors
of AMI after the first year mirror the general secular
trend observed in survivors of MI, based on the results
of epidemiological studies describing morbidity and
mortality trends covering at least 10 years in long-term
(>1 year) survivors of AMI.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Flow chart of systematic literature searches.
AMI acute myocardial infarction
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Systematic review
Literature searches were conducted in June 2015 in
Embase, MEDLINE, and the Cochrane Database of Sys-
tematic Reviews to identify epidemiological studies of
long-term (≥10-year) morbidity and mortality trends in
individuals who had experienced an AMI more than
1 year previously. The following search string was used:
((acute coronary syndrome.mp.) OR ((myocardium OR
myocardial) AND (ischemi* OR ischaemi*)).mp. OR (cor-
onary heart disease.mp.) OR (coronary artery disease.mp.)
OR (myocardial infarction.mp.) OR (unstable angina.mp.))
AND ((natural history.mp.) OR (longitudinal study.mp.)
OR (survival.mp.) OR ((secular or time) adj1 trend*).mp.
OR ((long term or long-term) adj1 prognosis).mp. OR
(prognosis adj1 (following or after)).mp.) OR ((impact and
(risk factor or model)).ab. OR (prognos* and model).ab.
OR (attribut* risk.ab.)) NOT (clinical trial.mp.). Searches
were limited to studies in adults that were published in
the English language from 1 January 2010.
To be eligible for inclusion, studies needed to present
10-year data for trends analysis of mortality or other
outcomes of atherosclerotic CV disease beyond the first
year in survivors of AMI. A flow chart of the literature
searches is depicted in Fig. 1.
Data collection
The following data were extracted: study characteristics
(study region, data source, study years, study population,
number of included individuals, mean age, proportion of
men, and amount of follow-up time); and all-cause mor-




The initial search identified 14,440 articles, of which
14,310 were excluded based on a review of the title and/
or abstract and 130 underwent full-text review (Fig. 1).
Following full-text review, a further 117 articles were ex-
cluded (Fig. 1 lists reasons for exclusion and the corre-
sponding number of articles excluded). Thirteen articles
fulfilled the inclusion criteria and did not meet the ex-
clusion criteria [11–23].
Study characteristics
The characteristics of the included studies are summa-
rized in Table 1. Four studies were conducted in Sweden
[12, 13, 18, 21], one study (with several subgroups and
follow-up times) was carried out in the Netherlands [11,
14–17, 22], and one study each took place in Denmark
[19], Spain [23] and the United Kingdom [20]. National
or regional registries were used as data sources in the
four Swedish studies [12, 13, 18, 21], the Danish study[19], and the study from the United Kingdom [20],
whereas data from Spain [23] and the Netherlands [11,
14–17, 22] were from single-center studies. Study years
covered ranged from 1985 to 2010. The number of in-
cluded individuals in each study ranged from 1393 to
175,216, mean patient age ranged from 56 years to
81 years, and the proportion of men ranged from 49%
to 81%.All-cause mortality
Incidence
Data on all-cause mortality were provided for six study
populations, described in 11 articles (Table 2) [11–18,
20, 22, 23]. Information on secular trends in all-cause
mortality was provided for five study populations, all of
which showed a consistent decrease when advancing
Table 1 Characteristics of included studies (eight study populations; 13 articles)
Study region Data source(s) Study
years











≥30 years with first
MI and without
prior diabetes

















for first MI (no prior
HF or CAD)
175,216 69 64 3 Shafazand
et al. 2011
[21]
RIKS-HIA 1996–2007 Individuals with first
STEMI




1987–2006 Individuals with first
MI aged 25–54 years







1985–2006 Individuals with first
MI









With NSTEMIa 7614 63 70 3 Nauta et al.
2011 [15]
With STEMIa 6820 61 75 3 Nauta et al.
2011 [15]
10 Snelder et al.
2013 [22]
With renal impairmentb 8632 Up to 20 Nauta et al.
2013 [17]




4671 Up to 20 Deckers et
al. 2013 [11]



























CAD coronary artery disease, CALIBER CArdiovascular disease research using LInked BEspoke studies and electronic health Records, CHD coronary heart disease,
CPRD Clinical Practice Research Datalink, HES Hospital Episodes Statistics, HF heart failure, ICCU intensive coronary care unit, MI myocardial infarction, MINAP
Myocardial Ischaemia National Audit Project registry, MONICA MONItoring trends and determinants in CArdiovascular disease, NR not reported, NSTEMI non-ST-
elevation myocardial infarction, ONS Office for National Statistics, RIKS-HIA Register of Information and Knowledge about Swedish Heart Intensive care Admissions,
STEMI ST-elevation myocardial infarction
aOf 14,434 individuals hospitalized for MI
bOf 12,087 individuals hospitalized for MI
cOf 11,324 individuals hospitalized for MI
dFollow-up started 6 months after the event
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15, 18, 22, 23]. Data for time periods starting 1 year after
the event were shown graphically and were not reported
separately.Relative risk
Relative risk analyses for all-cause death from 1 year
after the AMI were reported in one study, conducted
in Denmark (Table 3) [19]. The reference population
Table 2 All-cause mortality (six study populations; 11 articles)
Reference Assessment Mortality/survival
Viana-Tejedor et al. 2015 [23] Mortality in years 1–5 in patients alive
1 year after MIa
• Mortality 1988–1993: 26.9% (42/156); 1994–1998: 32.5% (66/203); 1999–2003:
23.7% (57/241); 2004–2008: 15.4% (48/311)
• 1-year and 5-year mortality decreased significantly over the
20-year period of study (p < 0.001)
Jernberg et al. 2011 [13] Risk of death up to 12 years after event • Time trends show risk of death 1996–1997 > 1998–1999 > 2000–2001 >
2002–2003 > 2004–2005 > 2006–2007b
Nielsen et al. 2014 [18] Survival probability for 4 years after event • For men, time trends show survival probability 1987–1991 < 1992–1996
< 1997–2001 < 2002–2006b
• For women, time trends show survival probability 1987–1991 <
1992–1996 < 1997–2001, but levels for 2002–2006 were similar to
those for 1997–2001b
Isaksson et al. 2011 [12] Survival up to 24 years after event • Time trends show survival 1985–1988 < 1989–1994 < 1995–2000 < 2001–2006b
• Survival in women was generally higher than that for men before 2000, but
similar for men and women after 2000
Nauta et al. 2011 [15] Survival for 3 years after event in patients
with NSTEMI
• Time trends show survival 1985–1990 < 1990–2000 < 2000–2008b
Snelder et al. 2013 [22] Mortality for up to 10 years after event in
patients with STEMI
• Time trends show mortality 1985–1990 > 1990–2000 > 2000–2008b
Nauta et al. 2013 [17] Mortality for up to 20 years after event
according to renal function
• Time trends for mortality stage 4–5 chronic kidney disease > stage 3 >
stage 2 > normal kidney functionb
Nauta et al. 2012 [14] Mortality for up to 20 years after event
according to diabetes status
• Mortality was higher in patients with diabetes than in those without
• There was an increase in the risk of presenting with diabetes during the
study period
• Time trends show mortality 1985–1989 > 1990–1999 > 2000–2008 in patients
with diabetes, and 1985–1989 ≈ 1990–1999 > 2000–2008 in patients without
diabetesb
Deckers et al. 2013 [11] Mortality for up to 20 years after event
according to glucose levels
• Mortality was highest in patients with severe hyperglycemia, followed by
those with mild hyperglycemia, and was lowest in those with normal
glucose levelsb
Nauta et al. 2012 [16] Mortality for up to 20 years after event
according to sex
• From 1985 to 2008, age at presentation increased and patients were
more likely to have diabetes or anemia at presentation
• Adjusted 20-year mortality was significantly lower in women than in men
Rapsomaniki et al. 2014 [20] Cumulative all-cause mortality up to
5.5 years after eventc
• Mortality in stable patients after NSTEMI > after STEMIb
MI myocardial infarction, NSTEMI non-ST-elevation myocardial infarction, STEMI ST-elevation myocardial infarction
aCalculated from data reported in the study
bAll shown on curve; actual values not reported for time starting 1 year after the event
cFollow-up started 6 months after the event
Table 3 All-cause death: relative risk analysis (one study population; one article)
Reference Assessment Relative risk analysis
Norgaard et al. 2010 [19] Relative risk (95% CI) versus reference population at 1–3 years and
3–5 years after MI during time periods 1997–2001 and 2001–2006
Men
1997–2001: 1–3 years, 1.42 (1.36–1.49); 3–5 years,
1.38 (1.31–1.45)
2001–2006: 1–3 years, 1.47 (1.39–1.55); 3–5 years,
1.46 (1.32–1.62)
Women
1997–2001: 1–3 years, 1.90 (1.81–2.00); 3–5 years,
1.84 (1.74–1.94)
2001–2006: 1–3 years, 2.02 (1.91–2.15); 3–5 years,
1.80 (1.60–2.02)
CI confidence interval, MI myocardial infarction
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above, with no prior prescriptions for glucose-lowering
drugs and no history of MI [19]. The relative risk of all-
cause death was increased at 1–3 years and 3–5 years after
MI compared with the reference population, and was
higher in women than in men (Table 3) [19]. Relative risk
values for the time period January 1997–June 2001 were
similar to those for the time period July 2001– December
2006 [19].
Another study compared estimated mortality in the
study population (aged 25–54 years) in the 4 years after
the index AMI with that expected in the general popula-
tion, but data from 1 year after the event were not re-
ported separately [18]. The excess in observed versus
expected mortality decreased from early to more recent
study periods in men, but less so in women [18].Risk factors
Several risk factors were identified that led to worse out-
comes, as follows. Mortality was higher in individuals
with diabetes than in those without diabetes across study
periods [14]. Mortality increased with increasing severity
of hyperglycemia [11] and with decreasing renal function
[17]. It was lower in women than in men [12, 16], but
the rates became more similar between the sexes in
more recent years [12, 18]. As expected, mortality in-
creased with age [12]. Significant risk factors for all-
cause death in patients who had experienced STEMI
and non-ST-elevation myocardial infarction (NSTEMI)
included increasing age, smoking, hypertension, diabetes,
peripheral artery disease, history of stroke, chronic kidney
disease, chronic obstructive pulmonary disease, chronic
liver disease, and history of cancer [20]. Primary percu-
taneous coronary intervention was shown to lower all-
cause mortality in patients with STEMI [23].Table 4 Cardiovascular outcomes: incidence (two study populations
Reference Assessment
Shafazand et al. 2011 [21] HF at 1–3 years in patients surviving 1 year
without HF
Rapsomaniki et al. 2014 [20] Cumulative non-fatal MI/coronary death
risk up to 5.5 years after eventa
HF heart failure, MI myocardial infarction, NSTEMI non-ST-elevation myocardial infar
aFollow-up started 6 months after the event
bAll shown on curve; actual values not reported for time starting 1 year after the evCV outcomes
Incidence
Incidence data for CV outcomes (heart failure [21], non-
fatal MI/coronary death [20]) were provided in two studies
(Table 4) [20, 21]. The incidence of heart failure at 1–3
years in patients surviving 1 year without heart failure de-
creased over time, ranging from 2.32% in the earliest study
period (1993–1995) to 1.47% in the most recent study
period (2002–2004) in the 35–64-year age group, and
from 5.03% in the earliest to 4.28% in the most recent
study period in the 65–84-year age group (p for trend
<0.001 in both age groups) [21]. No data were provided
that compared the incidence of CV outcomes or mortality
with those in the general population.Relative risk
Relative risk analyses for CV outcomes (recurrent MI, CV
death) were reported in one study, conducted in Denmark
(Table 5) [19]. The relative risks of recurrent MI and CV
death increased at 1–3 years and 3–5 years after MI com-
pared with the reference population, and were higher in
women than in men (Table 5) [19]. Relative risks for the time
period 1997–2001 were similar to those for 2001–2006 [19].Risk factors
Several risk factors were identified that led to worse out-
comes, as follows. The incidence of non-fatal MI/coronary
death 1 year to 5.5 years after acute coronary syndromes
in stable patients was highest after NSTEMI, followed by
unspecified MI and then STEMI [20]. Identified significant
risk factors for non-fatal MI/coronary death in patients
with STEMI and NSTEMI included increasing age,
smoking, hypertension, diabetes, peripheral artery disease,
history of stroke, chronic kidney disease, and chronic ob-














Cumulative risk of non-fatal MI/coronary death was shown to increase
further after 1 year for up to 5.5 years; cumulative risk of death in stable
patients after NSTEMI > MI (type unspecified) > after STEMIb
ction, STEMI ST-elevation myocardial infarction
ent
Table 5 Cardiovascular outcomes: relative risk (one study population; one article)
Reference Assessment Risk analysis
Norgaard et al. 2010 [19] Relative risk (95% CI) of recurrent MI versus reference
population at 1–3 years and 3–5 years after MI during
time periods 1997–2001 and 2001–2006
Men
1997–2001: 1–3 years, 2.99 (2.80–3.18); 3–5 years, 2.67 (2.48–2.87)
2001–2006: 1–3 years, 2.92 (2.69–3.17); 3–5 years, 2.70 (2.30–3.17)
Women
1997–2001: 1–3 years, 5.67 (5.25–6.11); 3–5 years, 4.33 (3.93–4.78)
2001–2006: 1–3 years, 5.64 (5.13–6.21); 3–5 years, 5.15 (4.24–6.25)
Relative risk (95% CI) of CV death versus reference
population at 1–3 years and 3–5 years after MI during
time periods 1997–2001 and 2001–2006
Men
1997–2001: 1–3 years, 2.11 (2.00–2.23); 3–5 years, 1.99 (1.88–2.11)
2001–2006: 1–3 years, 2.14 (2.00–2.28); 3–5 years, 2.10 (1.86–2.34)
Women
1997–2001: 1–3 years, 2.80 (2.64–2.97); 3–5 years, 2.63 (2.46–2.81)
2001–2006: 1–3 years, 2.92 (2.72–3.13); 3–5 years, 2.77 (2.42–3.17)
CI confidence interval, CV cardiovascular, MI myocardial infarction
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This systematic literature review reveals consistent im-
provements from early to more recent periods in secular
trends for long-term survival and CV outcomes after
MI. However, compared with the general population, MI
survivors remain at higher risk, particularly older indi-
viduals and patients with comorbid hypertension, dia-
betes, peripheral artery disease, or history of stroke. In
the single study that compared survival after the first
year with that of the general population, there was a lack
of improvement between the time periods 1997–2001
and 2001–2006; most of the decrease in mortality would
therefore seem to occur during the first year [19].
Secular trends data focusing on outcomes specifically
in survivors of MI after 1 year are scarce, with only one
study in this review reporting such information [19]. In
that study, a general population of similar age was in-
cluded as a reference, and the relative risk of all-cause
death was shown to be increased at both 1–3 years and
3–5 years after MI compared with the reference popula-
tion [19]. These data are supported by those of a re-
cently published, large, four-country analysis, which
showed an annual risk of death 1 year onwards after MI
that was more than double that of a similar general
population age group, with about half of deaths due to
CV disease [10]. The four-country analysis used “big
data” from hospital health records to assess long-term
CV disease outcomes starting 1 year after the most re-
cent discharge following AMI. It was conducted in the
United States and three European countries, and in-
cluded more than 100,000 survivors of MI aged 65 years
and older.
Studies have shown the increased risk of CV events in
individuals after MI to be higher in the first year follow-
ing the index MI than in subsequent years [9, 10]. In a
large Swedish registry study that formed part of thefour-country analysis which included 97,254 patients dis-
charged after MI, the risk of non-fatal MI, non-fatal
stroke, or CV death (primary composite end point) during
the first year after the index MI was 18.3% [9]. Although
the risk was lower in the subsequent 3 years than in the
first year, it remained relatively high with about one in five
patients without a combined end point during the first
year having a non-fatal MI, non-fatal stroke, or CV death
during the following 3 years [9]. Similarly, in the four-
country analysis, death, stroke, or further MI after the first
year following an MI occurred in about one-third of pa-
tients during the subsequent 3 years [10].
The high risk of vascular events after 1 year post-MI sug-
gests that prolonged surveillance beyond 12 months is re-
quired in this patient group. Results from a recent clinical
trial suggest that prolonged dual antiplatelet therapy
(DAPT) beyond the first year after an AMI is beneficial in
terms of preventing vascular events [24]. In the DAPT study
in patients treated with a drug-eluting stent, of whom 31%
presented with AMI, prolonged DAPT beyond 12 months
significantly lowered the cumulative incidence of stent
thrombosis and of major CV and cerebrovascular
events during the subsequent 18 months compared with
acetylsalicylic acid alone [25]. Current guidelines
recommend DAPT for 12 months for secondary prevention
[26–29], with European Society of Cardiology guidelines
noting that the duration may be extended (up to 30 months)
in selected patients, if required [27]. In patients stable 1 year
after an AMI, validated prognostic models based on indi-
vidual patient risk profiles can help to inform a decision of
whether or not to prolong DAPT [30].
Studies in the current review show a particularly high
risk of vascular events after MI in older individuals and
in patients with hypertension, diabetes, peripheral artery
disease, or history of stroke [14, 20]. Strong associations
between the risk of subsequent MI, stroke, or death and
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history of stroke were also revealed by the four-country
analysis, which further identified comorbid heart failure,
renal disease, and chronic obstructive pulmonary disease
as risk factors [10]. These results indicate a particular
need for better treatment options in these high-risk pa-
tient groups.
The current review highlights large information gaps
for outcomes that occur 1 year or more after the index
MI. Although most studies show time trends graphically,
they do not report actual data values separately for the
time period starting from 1 year post-MI. Thus, it is dif-
ficult to attribute differences and trends in longer-term
survival to specific time periods after the index event. In
addition, studies that report mortality and incidence data
for the time period starting 1 year after the index event
mostly present these as absolute values rather than
values relative to a control population, making it difficult
to assess to what extent the data from 1 year after the
event differ from those in the general population.
Conclusions
In conclusion, there have been consistent improvements
in secular trends for long-term survival and CV out-
comes after MI. However, MI survivors remain at higher
risk than the general population, particularly if there are
additional risk factors such as older age, hypertension,
or diabetes, all of which lead to worse outcomes.
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